Cemdisiran Recruiting Phase 3 Trials for Paroxysmal Nocturnal Haemoglobinuria (PNH) Treatment
| Indications | Status | Purpose | Phase |
|---|---|---|---|
| Recruiting | Treatment | 3 |
| clinicaltrials.gov Identifier | Title | Drugs |
|---|---|---|
| NCT05133531 | Ravulizumab-Controlled Non-Inferiority Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy |